TWiV discusses genetic evidence of susceptible wildlife in SARS-CoV-2 positive samples at the Huanan Wholesale Seafood Market, polio cases in African linked to a new polio vaccine that was designed to not cause the disease, and structural conservation of hepatitis B virus capsid proteins over millions of years despite a shift from a naked to an enveloped capsid.
In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Jason writes: Dear Twiv, I think I can add a tiny bit more on why the Department of Energy might be releasing a report on SARS CoV-2 origins. Rich was spot on, but here’s a…
TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.
In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.
TWiV reviews an outbreak of Marburg hemorrhagic fever in Equatorial Guinea, wild poliovirus type 3 shedding from a laboratory in the Netherlands, and white-tailed deer as a reservoir for previous SARS-CoV-2 variants of concern.
Volker writes: Dear Vincent, dear TWIVos, I’m writing from Bern, Switzerland, on a sunny but chilly day with blue sky and -1°C (30°F). As you know, the XVIth International Nidovirus Symposium is taking place this…
TWiV gives an update on poliovirus in wastewater, and reveals a vast world of viroids that infect a wide range of host species in diverse ecosystems.
In his weekly clinical update Dr. Griffin discusses poliovirus returns to New York wastewater, COVID-19 is more widespread in animals than we thought, increasing ventilation reduces SARS-CoV-2 airborne transmission in schools, the use of carbon dioxide monitoring to assess ventilation at a national infectious diseases conference, effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes, 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection, and long COVID outcomes at one year after mild SARS-CoV-2 infection.
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons, reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters, authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age, low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster, efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB, incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.